Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results
Rhea-AI Summary
Cognition Therapeutics (Nasdaq: CGTX) will report fourth quarter and full-year 2025 financial results on March 26, 2026 before market open. Management will host a conference call at 8:30 a.m. ET the same day to review results and provide a business update.
The live webcast with Q&A is available via a provided link or the company's Investor Relations website; an archive and presentation will be accessible for 90 days beginning about 10:30 a.m. ET on March 26, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – CGTX
On the day this news was published, CGTX gained 5.61%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows only TRDA moving (down) with no same-day peer news; no confirmed sector-wide move around this earnings-date announcement.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Clinical data update | Positive | +6.5% | Phase 2 SHIMMER data showing 86% slowing of decline on NPI-12. |
| Mar 02 | Program advancement | Positive | -2.8% | Plan to advance zervimesine toward registrational DLB psychosis program. |
| Feb 05 | Access program update | Positive | -2.9% | Extension of expanded access program for zervimesine in DLB. |
| Jan 27 | FDA meeting update | Positive | -4.3% | Completion of Type C FDA meeting on proposed Phase 2b DLB study. |
| Jan 06 | Clinical trial results | Positive | +0.7% | Phase 2 SHIMMER results showing safety and favorable effects vs placebo. |
Recent DLB-focused updates were generally positive in tone, but price reactions often lagged, with multiple mild selloffs following favorable clinical or regulatory news.
Over the last few months, Cognition Therapeutics has focused updates on zervimesine in dementia with Lewy bodies. A Phase 2 SHIMMER publication on Jan 6 highlighted safety and favorable efficacy signals. Subsequent Type C FDA interactions and an expanded access program in early 2026 further advanced the program. On Mar 2, the company outlined plans for a registrational DLB psychosis study, followed by new SHIMMER data at AD/PD 2026 on Mar 17. Today’s earnings-date notice fits into this backdrop of steady clinical and regulatory progress.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Dec 18, 2025 allows Cognition Therapeutics to offer up to $300,000,000 of various securities, including a separate at-the-market facility of up to $75,000,000 with Jefferies. Shelf usage count is 0, indicating no takedowns disclosed from this program in the provided data.
Market Pulse Summary
The stock moved +5.6% in the session following this news. A strong positive reaction aligns with a backdrop of constructive DLB data and regulatory progress. Prior news often saw mixed price follow-through despite favorable updates, so any large upside would markedly exceed the modest single-digit historical moves. Investors would need to weigh this enthusiasm against the company’s ability to utilize its $300,000,000 shelf and $75,000,000 ATM, which could introduce future equity supply.
AI-generated analysis. Not financial advice.
Conference Call and Live Webcast Scheduled for March 26, 2026
PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open. Management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update.
Conference Call Information
To participate in the conference call, dial (800) 445-7795 (U.S.) or (785) 424-1699 (international) and provide conference ID number CGTXQ4. The webcast with live Q&A will be accessible at https://viavid.webcasts.com/starthere.jsp?ei=1756394&tp_key=3ba1f3315f or via the Investor Relations section of Cognition’s website. An archive of the webcast and presentation will be available for 90 days beginning at approximately 10:30 a.m. ET on March 26, 2026.
About Cognition Therapeutics:
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve disorders. Our scientific approach builds on well-established biological pathways and translates across indications in which toxic oligomers drive disease progression, offering potential in dementia with Lewy bodies (DLB), Alzheimer’s disease, geographic atrophy, Parkinson’s, among others. The company’s lead candidate, zervimesine (CT1812), is an investigational once-daily oral therapy that has demonstrated promise in Phase 2 clinical trials in DLB and mild-to-moderate Alzheimer’s disease. Backed by nearly
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom, as well as statements regarding our regulatory plans are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
This press release was published by a CLEAR® Verified individual.
FAQ
When will Cognition Therapeutics (CGTX) release Q4 and full-year 2025 results?
What time is the Cognition Therapeutics (CGTX) conference call on March 26, 2026?
How can investors join the Cognition Therapeutics (CGTX) conference call and webcast?
Will Cognition Therapeutics (CGTX) provide a replay of the March 26, 2026 webcast?
What conference ID should participants use for the Cognition Therapeutics (CGTX) Q4 call?
Where can investors find the Cognition Therapeutics (CGTX) webcast link for the March 26, 2026 presentation?
